Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

NCT06495125 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT06495125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06495125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
July 31, 2024
Completion date
September 17, 2029
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung adenocarcinoma, refractory lung adenocarcinoma, stage iii lung cancer ajcc v8, stage iv lung cancer ajcc v8